Ameriprise
ZVRA icon

Ameriprise’s Zevra Therapeutics ZVRA Stock Holding History

Ameriprise’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-39,764
Closed -$195K – 4027
2024
Q2 		$195K Buy
39,764
+26,833
+208% +$127K ﹤0.01% 3695
2024
Q1 		$75K Buy
12,931
+1,673
+15% +$10.3K ﹤0.01% 3798
2023
Q4 		$73.7K Buy
+11,258
New +$52.7K ﹤0.01% 3838

Other funds holding ZVRA

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise's ZVRA Position: Q3 2024 in Review

Ameriprise sold out of Zevra Therapeutics (ZVRA) in Q3 2024, closing a stake of 39,764 shares — an estimated $195K sold.

Ameriprise first reported a position in ZVRA in Q4 2023 and held it in 3 quarters. The position peaked at $195K in Q2 2024. 108 funds tracked by Wall St. Rank hold ZVRA as of Q3 2024.

  • Ameriprise reported no remaining Zevra Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Ameriprise sold 39,764 Zevra Therapeutics shares in Q3 2024, an estimated $195K.
  • Ameriprise first reported a position in Zevra Therapeutics in Q4 2023 and held it in 3 quarters.
  • Ameriprise's Zevra Therapeutics position peaked at $195K in Q2 2024.
  • 108 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2024.

Based on Ameriprise's 13F filing for Q3 2024, filed 14 Nov 2024.